Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis [0.03%]
胃癌患者腹膜癌负荷较低的情况下行胃癌细胞减灭术及术后腹腔热灌注化疗的早期成本效益分析研究
Joost G E Verbeek,Karen van der Sluis,Marieke A Vollebergh et al.
Joost G E Verbeek et al.
Background: Gastric cancer patients with peritoneal carcinomatosis (PC) have a poor prognosis, with a median overall survival of 10 months when treated with systemic chemotherapy only. Cohort studies showed that cytoreduc...
Jonathan Broomfield,M Hill,F Chandler et al.
Jonathan Broomfield et al.
Background: The aim of this study was to pool multiple data sets to build a patient-centric, data-informed, natural history model (NHM) for Duchenne muscular dystrophy (DMD) to estimate disease trajectory across patient l...
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland [0.03%]
新辅助帕博利珠单抗联合化疗后继以辅助帕博利珠单抗治疗高危早期三阴性乳腺癌的经济学分析
Andrea Favre-Bulle,Min Huang,Amin Haiderali et al.
Andrea Favre-Bulle et al.
Aim: This study assessed the cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy plus placebo followed by adjuvant placebo for patients with...
Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment [0.03%]
痴呆患者的居住方式偏好：一项离散选择实验研究
Christian Speckemeier,Carina Abels,Klemens Höfer et al.
Christian Speckemeier et al.
Background: Dementia affects about 55 million people worldwide. Demographic change and shifting lifestyles challenge the organization of dementia care. A discrete choice experiment (DCE) was conducted to elicit preference...
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH) [0.03%]
肺动脉高压误诊的经济负担研究
Hilary M DuBrock,Hayley D Germack,Marjolaine Gauthier-Loiselle et al.
Hilary M DuBrock et al.
Background: The aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States. ...
Cost of Patients with Alzheimer's Disease in Spain According to Disease Severity [0.03%]
西班牙阿尔茨海默病患者的费用情况及其疾病的严重程度之间的关系
Laura Gómez Maldonado,Ricardo de Mora-Figueroa,Angélica López-Angarita et al.
Laura Gómez Maldonado et al.
Background: Alzheimer's disease (AD) has been associated with great healthcare and non-healthcare resource consumption. The aim of this study was to estimate the burden of AD in Spain according to disease severity from a ...
Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates [0.03%]
探究健康保险计划对生物类似药采纳率的影响
Jeremy Costin,Morgane C Mouslim,Mariana P Socal et al.
Jeremy Costin et al.
Background: We conducted a study to investigate the role of health insurance plans on biosimilar adoption among commercially insured patients in the USA. Flexible and rigid health plans may exhibit differing biosimilar co...
Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States [0.03%]
美国造血干细胞移植及其他免疫受损成人带状疱疹减毒活疫苗预防带状疱疹的效用及成本分析
Ahmed Salem,Elizabeth M La,Desmond Curran et al.
Ahmed Salem et al.
Introduction: Immunocompromised (IC) adults are at increased risk of developing herpes zoster (HZ) and HZ-related complications due to therapy or underlying disease. This study evaluated the cost effectiveness of recombin...
Patricia Kenny,Dan Liu,Denzil Fiebig et al.
Patricia Kenny et al.
Background/aims: The use and costs of health care rise substantially in the months prior to death, and although the use of palliative care services may be expected to lead to less costly care, the evidence is mixed. We an...
Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada [0.03%]
有关凯拉司测试的现实世界效用 确定英联邦加拿大不列颠哥伦比亚省转移性结直肠癌三线疗法中西妥昔单抗或帕尼单抗使用的性价比研究
Reka E Pataky,Stirling Bryan,Mohsen Sadatsafavi et al.
Reka E Pataky et al.
Background: Cetuximab and panitumumab, two anti-EGFR therapies, are widely used for third-line therapy of metastatic colorectal cancer (mCRC) with wild-type KRAS, but there remains uncertainty around their cost effectiven...